Company / Free Cash Flow
Stoke Therapeutics, Inc. Free Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$44.9M
FY2025
5-year range
-$82.7M / $44.9M
FY2021-FY2025
Trend
+154.3%
vs FY2024
Sector context
#56 of 194
Health Care
What the data says
At $45M, Stoke Therapeutics, Inc.'s free cash flow ranks #56 of 194 in the Health Care sector. Improved from -$36M to $45M over the past 2 years.
Based on SEC 10-K filings.
$45M in FY2025.
Improved from -$36M to $45M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#56 of 194 in Health CareTop 29% of 194This company $44.9M Sector average $470.6M
▼
-90.5% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 154.3% year-over-year.
- Ranks #56 out of 194 companies in the Health Care sector.
- Lowest free cash flow in the period was in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.9M | +154.3% |
| FY2024 | -$82.7M | -130.8% |
| FY2023 | -$35.8M | +47.4% |
| FY2022 | -$68.1M | +0.0% |
| FY2021 | -$68.1M | -57.4% |
| FY2020 | -$43.3M | -32.4% |
| FY2019 | -$32.7M | -174.7% |
| FY2018 | -$11.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026